Ticker Details
REGENXBIO Inc. Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
IPO Date:	September 17, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$412.07M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.77 | 2.90%
Avg Daily Range (30 D):	$0.41 | 3.41%
Avg Daily Range (90 D):	$0.40 | 3.18%

Institutional Daily Volume
Avg Daily Volume:	.38M
Avg Daily Volume (30 D):	.89M
Avg Daily Volume (90 D):	.65M

Trade Size
Avg Trade Size (Sh.):	73
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	66

Institutional Trades
Total Institutional Trades:	3,364
Avg Institutional Trade:	$1.92M
Avg Institutional Trade (30 D):	$1.14M
Avg Institutional Trade (90 D):	$1.26M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.16M
Avg Closing Trade (30 D):	$1.06M
Avg Closing Trade (90 D):	$1.04M
Avg Closing Volume:	82.34K

News

Feb 23, 2026 @ 6:44 PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENX... Source: Rosen Law Firm

Feb 23, 2026 @ 5:00 PM Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO ... Source: Bronstein, Gewirtz & Grossman Llc

Feb 20, 2026 @ 11:47 PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REG... Source: Rosen Law Firm

Feb 20, 2026 @ 7:51 PM RGNX Investors Have Opportunity to Lead REGENXBIO ... Source: The Schall Law Firm

Feb 19, 2026 @ 5:00 PM Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO ... Source: Bronstein, Gewirtz & Grossman Llc

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-3.46	$-1.2	$-1.38
Diluted EPS	$-3.46	$-1.2	$-1.38
Revenue	$161.32M	$29.73M	$21.36M
Gross Profit
Net Income / Loss	$-177.92M	$-61.94M	$-70.87M
Operating Income / Loss	$-154.93M	$-52.41M	$-63.28M
Cost of Revenue
Net Cash Flow	$2.19M	$-20.76M	$-50.55M
PE Ratio